Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant patients: preliminary results from the Myfortic Prospective Multicenter Study
- 1 March 2004
- journal article
- research article
- Published by Elsevier in Transplantation Proceedings
- Vol. 36 (2) , S521-S523
- https://doi.org/10.1016/j.transproceed.2004.01.037
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Enteric Coated Mycophenolate Sodium is Therapeutically Equivalent to Mycophenolate Mofetil in de novoRenal Transplant PatientsAmerican Journal of Transplantation, 2004
- Mycophenolate Mofetil Dose Reduction and the Risk of Acute Rejection after Renal TransplantationJournal of the American Society of Nephrology, 2003
- The impact of mycophenolate mofetil dosing patterns on clinical outcome after renal transplantationClinical Transplantation, 2003
- Enteric-coated mycophenolate sodium: results of two pivotal global multicenter trialsTransplantation Proceedings, 2001
- Therapeutic equivalence of mycophenolate sodium versus mycophenolate mofetil in de novo renal transplant recipientsTransplantation Proceedings, 2001
- Adverse Gastrointestinal Effects of Mycophenolate MofetilDrug Safety, 2001
- MYCOPHENOLATE MOFETIL REDUCES LATE RENAL ALLOGRAFT LOSS INDEPENDENT OF ACUTE REJECTIONTransplantation, 2000
- A BLINDED, RANDOMIZED CLINICAL TRIAL OF MYCOPHENOLATE MOFETIL FOR THE PREVENTION OF ACUTE REJECTION IN CADAVERIC RENAL TRANSPLANTATION1Transplantation, 1996
- MYCOPHENOLATE MOFETIL FOR THE PREVENTION OF ACUTE REJECTION IN PRIMARY CADAVERIC RENAL ALLOGRAFT RECIPIENTSTransplantation, 1995
- Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejectionThe Lancet, 1995